信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT
UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE THIRD QUARTER OF 2025

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the third quarter of 2025, the Company achieved total product revenue exceeding RMB3.3 billion, maintaining a robust growth of approximately 40% year-on-year, dual-driven by oncology and general biomedicine product portfolio expansion. During the quarter: 1) Innovent, as an established leading brand in oncology, sustained growth from major products including TYVYT® (sintilimab injection), with rising revenue contribution from newly-launched oncology products; 2) products in the general biomedicine franchise continued to unlock potential and revenue contribution expanded rapidly. Specifically, mazdutide, SINTBILO® (tafolecimab injection) and SYCUME® (teprotumumab N01 injection) have achieved accelerated uptake through enhanced market access and marketing channel strategies. Furthermore, a second indication of mazdutide for type 2 diabetes has received approval by the National Medical Products Administration of China, providing a high-quality innovative treatment option for broader patient population.

The Company is committed to its core strategies of sustainable growth and global innovation, with a solid pipeline built in oncology and general biomedicine (which includes cardiovascular and metabolism, autoimmune, and ophthalmology). To date, the Company has 16 approved products, two new drug applications under regulatory review, four assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. The year 2025 is a significant year for the Company as it enters a new era of sustainable growth and global innovation, moving steadily towards its vision of becoming a global premier biopharmaceutical company.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such, the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
October 30, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as independent non-executive Directors.